A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection

Something to learn from failure?

Francesco Di Mario, Lucas G. Cavallaro, Antonio Nouvenne, Nicoletta Stefani, Giulia M. Cavestro, Veronica Iori, Marta Maino, Giuseppe Comparato, Libera Fanigliulo, Ester Morana, Alberto Pilotto, Laura Martelli, Mario Martelli, Gioacchino Leandro, Angelo Franzè

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Curcumin is the principal element of turmeric powder extracted from the root of Curcuma longa. Studies on curcumin have demonstrated some anti-Helicobacter pylori activity as well as immunomodulating properties. N-acetylcysteine and lactoferrin with their respective mucolytic and antibacterial activities might also be effective in H. pylori eradication therapy. Aim: To determine if a 7-day non-antibiotic therapy comprised of curcumin, lactoferrin, N-acetylcysteine, and pantoprazole was effective for eradication of H. pylori infection and reduction of gastric inflammation, assessed by serum pepsinogens and relief of symptoms. Subjects and Methods: Twenty-five consecutive H. pylori-positive patients (12 males, mean age 50 ± 12 years, range 31-76) with functional dyspepsia were enrolled. Patients were administered for 7 days curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., and pantoprazole 20 mg b.i.d. H. pylori status and upper gastrointestinal symptoms were assessed by 13C-urea breath test and a scale of upper gastrointestinal symptoms intensity (absent, mild, moderate, and severe), as well as a blood test for serum pepsinogens (sPGI, sPGII), gastrin-17 (G-17), and anti-H. pylori IgG (IgG-Hp) at baseline (T0) and after 2 months (T1). Results: Three of 25 patients (12%) were cured of H. pylori infection. A significant decrease in the overall severity of symptoms (T0: 6, interquartile range [IQR]: 4.5-8; T1: 2, IQR: 2-3; p ≤.001), and sPGII (T0: 16 μg/L, IQR: 13-22; T1: 10 μg/L, IQR: 8-16; p ≤.001) and sPGI (T0: 82 μg/L, IQR: 67-97; T1: 74 μg/L, IQR: 62-94; p =.02) levels were observed after 2 months of the treatment. IgG and G-17 values did not significantly decrease after 2 months. Conclusions: This novel therapy was not effective for H. pylori eradication. However, despite the bacterium persistence, significant improvement of dyspeptic symptoms and reduction of serologic signs of gastric inflammation were observed after 2 months at the end of the 7-day treatment schedule.

Original languageEnglish
Pages (from-to)238-243
Number of pages6
JournalHelicobacter
Volume12
Issue number3
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Curcumin
Helicobacter Infections
Helicobacter pylori
Lactoferrin
Acetylcysteine
Pepsinogens
Curcuma
Immunoglobulin G
Therapeutics
Stomach
Expectorants
Inflammation
Breath Tests
Dyspepsia
Hematologic Tests
Serum
Powders
Urea
Appointments and Schedules
Bacteria

Keywords

  • Curcumin
  • Dyspepsia
  • H. pylori eradication
  • Helicobacter pylori
  • Lactoferrin
  • N-acetylcysteine

ASJC Scopus subject areas

  • Gastroenterology
  • Microbiology

Cite this

A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection : Something to learn from failure? / Di Mario, Francesco; Cavallaro, Lucas G.; Nouvenne, Antonio; Stefani, Nicoletta; Cavestro, Giulia M.; Iori, Veronica; Maino, Marta; Comparato, Giuseppe; Fanigliulo, Libera; Morana, Ester; Pilotto, Alberto; Martelli, Laura; Martelli, Mario; Leandro, Gioacchino; Franzè, Angelo.

In: Helicobacter, Vol. 12, No. 3, 06.2007, p. 238-243.

Research output: Contribution to journalArticle

Di Mario, F, Cavallaro, LG, Nouvenne, A, Stefani, N, Cavestro, GM, Iori, V, Maino, M, Comparato, G, Fanigliulo, L, Morana, E, Pilotto, A, Martelli, L, Martelli, M, Leandro, G & Franzè, A 2007, 'A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: Something to learn from failure?', Helicobacter, vol. 12, no. 3, pp. 238-243. https://doi.org/10.1111/j.1523-5378.2007.00497.x
Di Mario, Francesco ; Cavallaro, Lucas G. ; Nouvenne, Antonio ; Stefani, Nicoletta ; Cavestro, Giulia M. ; Iori, Veronica ; Maino, Marta ; Comparato, Giuseppe ; Fanigliulo, Libera ; Morana, Ester ; Pilotto, Alberto ; Martelli, Laura ; Martelli, Mario ; Leandro, Gioacchino ; Franzè, Angelo. / A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection : Something to learn from failure?. In: Helicobacter. 2007 ; Vol. 12, No. 3. pp. 238-243.
@article{218b92660a36430fb0da39eaec24c479,
title = "A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: Something to learn from failure?",
abstract = "Background: Curcumin is the principal element of turmeric powder extracted from the root of Curcuma longa. Studies on curcumin have demonstrated some anti-Helicobacter pylori activity as well as immunomodulating properties. N-acetylcysteine and lactoferrin with their respective mucolytic and antibacterial activities might also be effective in H. pylori eradication therapy. Aim: To determine if a 7-day non-antibiotic therapy comprised of curcumin, lactoferrin, N-acetylcysteine, and pantoprazole was effective for eradication of H. pylori infection and reduction of gastric inflammation, assessed by serum pepsinogens and relief of symptoms. Subjects and Methods: Twenty-five consecutive H. pylori-positive patients (12 males, mean age 50 ± 12 years, range 31-76) with functional dyspepsia were enrolled. Patients were administered for 7 days curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., and pantoprazole 20 mg b.i.d. H. pylori status and upper gastrointestinal symptoms were assessed by 13C-urea breath test and a scale of upper gastrointestinal symptoms intensity (absent, mild, moderate, and severe), as well as a blood test for serum pepsinogens (sPGI, sPGII), gastrin-17 (G-17), and anti-H. pylori IgG (IgG-Hp) at baseline (T0) and after 2 months (T1). Results: Three of 25 patients (12{\%}) were cured of H. pylori infection. A significant decrease in the overall severity of symptoms (T0: 6, interquartile range [IQR]: 4.5-8; T1: 2, IQR: 2-3; p ≤.001), and sPGII (T0: 16 μg/L, IQR: 13-22; T1: 10 μg/L, IQR: 8-16; p ≤.001) and sPGI (T0: 82 μg/L, IQR: 67-97; T1: 74 μg/L, IQR: 62-94; p =.02) levels were observed after 2 months of the treatment. IgG and G-17 values did not significantly decrease after 2 months. Conclusions: This novel therapy was not effective for H. pylori eradication. However, despite the bacterium persistence, significant improvement of dyspeptic symptoms and reduction of serologic signs of gastric inflammation were observed after 2 months at the end of the 7-day treatment schedule.",
keywords = "Curcumin, Dyspepsia, H. pylori eradication, Helicobacter pylori, Lactoferrin, N-acetylcysteine",
author = "{Di Mario}, Francesco and Cavallaro, {Lucas G.} and Antonio Nouvenne and Nicoletta Stefani and Cavestro, {Giulia M.} and Veronica Iori and Marta Maino and Giuseppe Comparato and Libera Fanigliulo and Ester Morana and Alberto Pilotto and Laura Martelli and Mario Martelli and Gioacchino Leandro and Angelo Franz{\`e}",
year = "2007",
month = "6",
doi = "10.1111/j.1523-5378.2007.00497.x",
language = "English",
volume = "12",
pages = "238--243",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection

T2 - Something to learn from failure?

AU - Di Mario, Francesco

AU - Cavallaro, Lucas G.

AU - Nouvenne, Antonio

AU - Stefani, Nicoletta

AU - Cavestro, Giulia M.

AU - Iori, Veronica

AU - Maino, Marta

AU - Comparato, Giuseppe

AU - Fanigliulo, Libera

AU - Morana, Ester

AU - Pilotto, Alberto

AU - Martelli, Laura

AU - Martelli, Mario

AU - Leandro, Gioacchino

AU - Franzè, Angelo

PY - 2007/6

Y1 - 2007/6

N2 - Background: Curcumin is the principal element of turmeric powder extracted from the root of Curcuma longa. Studies on curcumin have demonstrated some anti-Helicobacter pylori activity as well as immunomodulating properties. N-acetylcysteine and lactoferrin with their respective mucolytic and antibacterial activities might also be effective in H. pylori eradication therapy. Aim: To determine if a 7-day non-antibiotic therapy comprised of curcumin, lactoferrin, N-acetylcysteine, and pantoprazole was effective for eradication of H. pylori infection and reduction of gastric inflammation, assessed by serum pepsinogens and relief of symptoms. Subjects and Methods: Twenty-five consecutive H. pylori-positive patients (12 males, mean age 50 ± 12 years, range 31-76) with functional dyspepsia were enrolled. Patients were administered for 7 days curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., and pantoprazole 20 mg b.i.d. H. pylori status and upper gastrointestinal symptoms were assessed by 13C-urea breath test and a scale of upper gastrointestinal symptoms intensity (absent, mild, moderate, and severe), as well as a blood test for serum pepsinogens (sPGI, sPGII), gastrin-17 (G-17), and anti-H. pylori IgG (IgG-Hp) at baseline (T0) and after 2 months (T1). Results: Three of 25 patients (12%) were cured of H. pylori infection. A significant decrease in the overall severity of symptoms (T0: 6, interquartile range [IQR]: 4.5-8; T1: 2, IQR: 2-3; p ≤.001), and sPGII (T0: 16 μg/L, IQR: 13-22; T1: 10 μg/L, IQR: 8-16; p ≤.001) and sPGI (T0: 82 μg/L, IQR: 67-97; T1: 74 μg/L, IQR: 62-94; p =.02) levels were observed after 2 months of the treatment. IgG and G-17 values did not significantly decrease after 2 months. Conclusions: This novel therapy was not effective for H. pylori eradication. However, despite the bacterium persistence, significant improvement of dyspeptic symptoms and reduction of serologic signs of gastric inflammation were observed after 2 months at the end of the 7-day treatment schedule.

AB - Background: Curcumin is the principal element of turmeric powder extracted from the root of Curcuma longa. Studies on curcumin have demonstrated some anti-Helicobacter pylori activity as well as immunomodulating properties. N-acetylcysteine and lactoferrin with their respective mucolytic and antibacterial activities might also be effective in H. pylori eradication therapy. Aim: To determine if a 7-day non-antibiotic therapy comprised of curcumin, lactoferrin, N-acetylcysteine, and pantoprazole was effective for eradication of H. pylori infection and reduction of gastric inflammation, assessed by serum pepsinogens and relief of symptoms. Subjects and Methods: Twenty-five consecutive H. pylori-positive patients (12 males, mean age 50 ± 12 years, range 31-76) with functional dyspepsia were enrolled. Patients were administered for 7 days curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., and pantoprazole 20 mg b.i.d. H. pylori status and upper gastrointestinal symptoms were assessed by 13C-urea breath test and a scale of upper gastrointestinal symptoms intensity (absent, mild, moderate, and severe), as well as a blood test for serum pepsinogens (sPGI, sPGII), gastrin-17 (G-17), and anti-H. pylori IgG (IgG-Hp) at baseline (T0) and after 2 months (T1). Results: Three of 25 patients (12%) were cured of H. pylori infection. A significant decrease in the overall severity of symptoms (T0: 6, interquartile range [IQR]: 4.5-8; T1: 2, IQR: 2-3; p ≤.001), and sPGII (T0: 16 μg/L, IQR: 13-22; T1: 10 μg/L, IQR: 8-16; p ≤.001) and sPGI (T0: 82 μg/L, IQR: 67-97; T1: 74 μg/L, IQR: 62-94; p =.02) levels were observed after 2 months of the treatment. IgG and G-17 values did not significantly decrease after 2 months. Conclusions: This novel therapy was not effective for H. pylori eradication. However, despite the bacterium persistence, significant improvement of dyspeptic symptoms and reduction of serologic signs of gastric inflammation were observed after 2 months at the end of the 7-day treatment schedule.

KW - Curcumin

KW - Dyspepsia

KW - H. pylori eradication

KW - Helicobacter pylori

KW - Lactoferrin

KW - N-acetylcysteine

UR - http://www.scopus.com/inward/record.url?scp=34247863959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247863959&partnerID=8YFLogxK

U2 - 10.1111/j.1523-5378.2007.00497.x

DO - 10.1111/j.1523-5378.2007.00497.x

M3 - Article

VL - 12

SP - 238

EP - 243

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 3

ER -